Golden Helix has officially announced the launch of VarSeq 3 and VSWarehouse 3.
According to certain reports, the stated solution brings to the fore an assortment of cloud-native deployment options optimized for AWS and Azure, expanded support for hybrid and on-premise support, as well as flexible licensing models like per-sample packaging tailored to small and mid-sized labs.
More on the same would reveal how, for the purpose of supporting these new deployment and licensing models, Golden Helix’s also packs together seamless integration of secondary analysis and expanded capabilities for long-read sequencing, including accurate detection and interpretation of repeat expansions.
As for the possible use cases, Golden Helix’s integrated solution is understood to be ideal, at launch, for high-throughput labs, national genome initiatives, and smaller diagnostic labs alike, delivering unmatched scalability, automation, and deployment flexibility.
Talk about the whole value proposition on a slightly deeper level, we begin from the promise of cloud-optimized and hybrid-ready deployments. This translates to how customers can deploy on AWS, Azure, or their own private infrastructure with full support for hybrid environments. The underlying architecture also treads up a long distance to support elastic compute provisioning, seamless updates, and integration with cloud-native storage solutions.
Markedly enough, these workloads can also scale dynamically based on demand, whether running on-prem, in the cloud, or across distributed clusters.
Next up, there is potential for secure collaboration and data federation. Here, Golden Helix’s VarSeq 3 and VSWarehouse 3 technology makes it possible for users to facilitate national-level genome data coordination and multi-site collaboration via fine-grained access control and secure data sharing.
Complementing this would be the availability of native integrations with cloud object storage and third-party NGS repositories that are tasked with streamlining cloud-to-cloud data transfer and federated analysis across institutions and geographies.
Another detail worth a mention is relates to the given solution’s per-sample licensing options. You see, for the first time, Golden Helix is introducing per-sample packages that give smaller labs, and the ones with seasonal or variable sample volumes, an access to enterprise capabilities. This it does without mandating the need for any upfront cost.
Hold on, we still have a few bits left to unpack, considering we haven’t yet expanded upon the solution’s bid to provide integration for secondary analysis.
In essence, one unified integration layer for secondary analysis should empower labs in the context of seamlessly connecting upstream pipelines with clinical interpretation workflows. Beyond that, users can also come expecting to automatically ingest, store, and analyze variant calls, alignment metrics, and quality control outputs from various tools.
We also haven’t touched upon a facility committed to automating full pipelines across clinical domains including pharmacogenomics, carrier screening, CNV, and repeat expansion analysis. Alongside that, we have built-in auto-classification and expert curated annotations that can cut down on interpretation time, and at the same time, support regulatory compliance.
Rounding up highlights would be VarSeq 3 and VSWarehouse 3 ability to deliver, at your disposal, neccesary support for long-read sequencing technologies, including repeat expansion detection critical for diagnosing rare disorders like Huntington’s disease and Fragile X. These capabilities further extend across both secondary and tertiary workflows.
Founded back in 1998, Golden Helix’s rise up the ranks stems from helping scientists and healthcare professionals find the all-important value within those rapidly increasing volumes of genomic data, produced by microarrays and next-generation sequencing. The company’s solutions are presently focused on identifying the cause of disease, improving the efficacy and safety of drugs, developing genomic diagnostics, and advancing the processes to reach upon personalized medicine.
Golden Helix’s excellence in what it does can also be understood once you consider its products and services have, thus far, been cited in 1,000s of peer-reviewed publications.
“With VarSeq 3 and its integration into VSWarehouse 3, we are equipping our customers with the infrastructure readiness and data ownership they need to operate at scale—whether in private cloud, hybrid, or fully cloud-native settings,” said Dr. Andreas Scherer, President and CEO of Golden Helix. “This release also expands access to our enterprise-grade platform through per-sample licensing, helping smaller and growing labs take advantage of our full suite of features as they scale.”
